Engineering Tlymphocytes is an emerging approach in a variety of biomedical applications. However, delivering large biologics to primaryTlymphocytes directly in vivo is technically challenging due to the low transfection efficacy. Herein, we investigated a library of synthetic lipid‐like molecules (lipidoids) for their capability of delivering mRNA into primaryTlymphocytes both ex vivo and in vivo. We
[EN] DISULFIDE COMPOUNDS FOR DELIVERY OF PHARMACEUTICAL AGENTS<br/>[FR] COMPOSÉS À BASE DE DISULFURE POUR L'ADMINISTRATION D'AGENTS PHARMACEUTIQUES
申请人:TUFTS UNVERSITY
公开号:WO2014134445A1
公开(公告)日:2014-09-04
A compound of formula the following formula:(I). In this formula, moieties A, B, X, R1, R2, and R3 are defined herein. Also disclosed are a nanocomplex that is formed of such a compound and a pharmaceutical agent, and a nanocomplex that is formed of a protein and a bioreducible compound.
[EN] NANOCOMPLEXES FOR DELIVERY OF SAPORIN<br/>[FR] NANOCOMPLEXES DESTINÉES À L'ADMINISTRATION DE SAPORINE
申请人:UNIV TUFTS
公开号:WO2014186366A1
公开(公告)日:2014-11-20
A nanocomplex, of particle size 50 nm to 1000 nm, containing saporin and a lipid-like compound, in which saporin binds to the lipid-like compound via non-covalent interaction or covalent bonding. The lipid-like compound has a hydrophilic moiety, a hydrophobic moiety, and a linker joining the hydrophilic moiety and the hydrophobic moiety. The hydrophilic moiety is optionally charged and the hydrophobic moiety has 8 to 24 carbon atoms. Also disclosed is a pharmaceutical composition containing such a nanocomplex and a pharmaceutically acceptable carrier. The nanocomplex is useful in treating diseases, such as cancer.